BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30449848)

  • 1. [Pemetrexed for Treatment of Nonsquamous Non-Small-Cell Lung Cancer].
    Omori Y; Enatsu S
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1609-1613. PubMed ID: 30449848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
    Patel JD; Paz-Ares L; Zinner RG; Barlesi F; Koustenis AG; Obasaju CK
    Clin Lung Cancer; 2018 Nov; 19(6):e823-e830. PubMed ID: 30369427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
    Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
    J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B
    Baldi M; Behera D; Kaur J; Kapoor R; Singh N
    Clin Lung Cancer; 2017 Jul; 18(4):432-435. PubMed ID: 28073680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.
    Stinchcombe TE; Borghaei H; Barker SS; Treat JA; Obasaju C
    Clin Lung Cancer; 2016 Jan; 17(1):1-9. PubMed ID: 26340853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
    Liang Y; Wakelee HA; Neal JW
    Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.
    Yoshida T; Okamoto T; Yano T; Takada K; Kohno M; Suda K; Takenoyama M; Oda Y; Maehara Y
    Anticancer Res; 2016 Dec; 36(12):6319-6326. PubMed ID: 27919952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
    Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
    Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
    Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
    Gautschi O; Rothschild SI; Li Q; Matter-Walstra K; Zippelius A; Betticher DC; Früh M; Stahel RA; Cathomas R; Rauch D; Pless M; Peters S; Froesch P; Zander T; Schneider M; Biaggi C; Mach N; Ochsenbein AF;
    Clin Lung Cancer; 2017 May; 18(3):303-309. PubMed ID: 27993482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
    Igawa S; Sato Y; Ishihara M; Kasajima M; Kusuhara S; Nakahara Y; Otani S; Fukui T; Katagiri M; Sasaki J; Masuda N
    Asian Pac J Cancer Prev; 2016; 17(7):3249-53. PubMed ID: 27509958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
    Zhong A; Xiong X; Shi M; Xu H
    Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed disodium for the treatment of NSCLC: an update.
    Hsu JY; Wakelee H
    Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
    Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.